The serotonin transporter gene polymorphism is associated with the susceptibility and the pain severity in Idiopathic Trigeminal Neuralgia patients by Wenyao Cui et al.
Cui et al. The Journal of Headache and Pain 2014, 15:42
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Background: To investigate the possible association between the serotonin transporter gene (5-HTTLPR) and rs
25531 polymorphism and the susceptibility and the pain severity in Trigeminal Neuralgia patients.
Methods: A total of 244 TN patients and 280 age and sex matched healthy volunteer were recruited. 5-HTTLPR and
rs 25531 genotyping were performed. All patients received the carbamazepine treatment and the treatment
response was evaluated at 6 months.
Results: The genotype distribution of 5-HTTLPR between TN patients and controls were significantly different. The
TN Patients had a higher prevalence of short-short genotype than controls. The short-short genotype carriers are
also significantly associated with higher pain severity and poorer carbamazepine treatment response compared to
the long-long genotype carriers. In contrast, the rs 25531 polymorphism was not associated with the susceptibility
to TN, neither with the pain severity and the treat response to carbamazepine.
Conclusion: The 5-HTTLPR polymorphism is associated with the susceptibility to TN and pain severity of TN.
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Trigeminal neuralgia (TN) is the most common type of
neuralgia in human adult [1,2]. TN is defined as sudden,
usually unilateral, severe, brief, stabbing recurrent episodes
of pain within the distribution of one or more branches
of the trigeminal nerve [3,4]. carbamazepine (CBZ) is cur-
rently widely used for the treatment of TN, although treat-
ment response varies among individual patient [5-8].
Serotonin (also known as 5-hydroxytryptamine, 5-HT)
is an important neuromodulator associated with a wide
range of physiological effects in the central nervous system.
Previous studies have revealed a critical role for 5-HT
in numerous physiological processes, including cell division,
neuronal migration, differentiation and synaptogenesis.
5-HT has been implicated in a series of pain disorders* Correspondence: wenyaocui01@126.com
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conditions mediated by the trigeminal system [9-12].
Serotonin transporter (5-HTT) is a key regulator of 5-HT
in neurological system. 5-HTT can inhibit 5-HT release
into the synaptic cleft, thereby terminating serotonergic
neurotransmission [13].
5-HTT protein is encoded by the SLC6A4 gene whose
transcriptional activity is regulated by a number of variations
[13,14]. The serotonin transporter gene (5-HTT)-linked
polymorphic region (5-HTTLPR) plays an important role
in regulating 5-HTT expression and thereby controlling
the concentration of serotonin (5-HT) in brain synapses
[15,16]. Recent studies reveal close associations between
the genetic variation in the 5-HTTLPR and rs25531
with several pain conditions. For example, 5-HTTLPR
gene polymorphism influences the analgesic response to
the short acting opioid Remifentanil in human [17]. The
5-HTTLPR polymorphism affects the pain modulation
at the supraspinal level [18]. In patients with chronicpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 The characteristics of patients and controls
TN (n = 244) Control (n = 280) P
Characteristics
Mean age (yrs) 55.06 (38.7-67.8) 54.93 (38.5-69.1) 0.876
Sex
Male 100 112 0.432
Female 144 168
Smoking status
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HTTLPR gene polymorphisms and pain perception
was reported. Genetic variation in the serotonin transporter
gene (5-HTTLPR, rs25531) confers the analgesic response
to the short acting opioid Remifentanil in humans [17].
To date, there is no study reporting the association
between 5-HTTLPR and the susceptibility to TN and its
clinical features, especially the pain severity and treatment
response to analgesics. Based on the role played by the
5-HTTLPR gene polymorphisms in other pain condi-
tions [17,18], we postulate that the 5-HTTLPR gene
polymorphisms might be also associated with the sus-
ceptibility to TN and with its clinical features.
Methods
Patients
This study included 244 patients diagnosed with idiopathic
TN who were treated at Pain department of the First
Affiliated Hospital, China Medical University from August
2008 to August 2012. The TN diagnosis was established
according to the International Association for the Study of
Pain (IASP) [19]. All patients have paroxysmal attacks of
pain, affecting one or more divisions of the trigeminal
nerve. Magnetic resonance imaging (MRI) of the whole
brain, with particular attention paid to the region of the
pons, was done for all subjects to rule out tumor, vascular
malformation, multiple sclerosis, or related conditions.
Also, complete neurological examinations were given
to all patients before treatment to check clinical symptoms.
A total of 280 age and sex matched healthy volunteer were
recruited from annual checkup visitors as control sub-
jects. All participants were genetically unrelated ethnic
Han Chinese people. The exclusion criteria included
central nervous system-related disease, pre-existing de-
pression/anxiety, pregnancy, diabetes mellitus, abnormal
laboratory baseline values, unstable psychiatric feature
(e.g., suicidal attempt), history of alcohol or drug depend-
ence, seizures, neurological illness or concomitant Axis
I psychiatric disorder, chronic inflammation disease and
cancer. This study received approval from the institutional
review boards of the First Affiliated Hospital, China
Medical University (2008-A-15B). All patients gave written
informed consent to participate in the present study.
Treatment and pain evaluation
All patients were treated with the traditional approach
of CBZ in monotherapy (400–800 mg/day, maximum
1200 mg/day) for 6 months. Patients who discounted the
treatment or went to interventional or surgical treatments
within 6 months were excluded. The degree of pain was
checked using Barrow Neurological Institute [20] scores [20].
Pain intensity scale before and 6 month after treatment was
evaluated. The improvement of pain symptom was defined
as at least one grade alleviation according BNI scores [21].DNA extraction and 5-HTTLPR genotyping
Genomic DNA was extracted from participants' peripheral
blood leukocytes using a DNA extraction kit (TianGen,
China). The promoter region of the SLC6A4 gene was
amplified using a 10 μl of PCR reagent mixture with a
forward primer set of 0.25 μM VIC-labeled and 0.25 μM
unlabeled, and 0.50 μM reverse primer and 250 μM dNTP
on the GeneAmp PCR System 9700 (Applied Biosystems,
Foster City, CA, USA). Here, 526 bp and 478 bp fragments
were called as a Long and a Short allele at 5-HTTLPR,
respectively. For the rs25531 polymorphism, the PCR prod-
uct was digested with restriction endonuclease MspI (New
England Biolabs Inc., Boston, MA, USA). The resulting
product was analyzed using an ABI3100 DNA Analyzer
and the Peak Scan Software v1.0 (Applied Biosystems).
Digested fragments with a size of 164–165 bp were deter-
mined as a G allele and indigested as an A allele.
Statistical analysis
The Fisher's exact Chi-square test was first used to com-
pare the frequency distribution of age, gender, smoking
status between TN patients and controls, if appropriate.
A chi square test was performed to assess Hardy–Weinberg
equilibrium in the TN patients and controls based on
allelic and genotypic frequencies. We performed multi-
variate logistic regression analysis to estimate the effect of
5-HTTLPR or rs25531 polymorphisms on risk factor for
TN in the presence of other known prognostic factors,
including age, sex and smoke. Analyses were performed
using the software SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
Table 2 The genotype distribution of HTTLPR between TN patients controls
Genotype TN Control Adjusted OR 95% CI Adjusted P
5-HTTLPR Long-long 58 23.77% 103 36.79% 1.000
Long-short 99 40.57% 129 46.07% 1.363 0.900 2.064 0.143
Short-short 87 35.66% 48 17.14% 3.219 1.997 5.187 0.000
Long 215 44.06% 335 59.82% 1.000
short 273 55.94% 225 40.18% 1.891 1.478 2.418 0.045
rs25531 AA 68 27.87% 75 26.79% 1.000
AG 114 46.72% 135 48.21% 0.931 0.617 1.406 0.735
GG 62 25.41% 70 25.00% 0.977 0.608 1.569 0.923
A 250 51.23% 285 50.89% 1.000
G 238 48.77% 275 49.11% 0.987 0.774 1.258 0.913
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Results
The characteristics of patients and controls are listed
in Table 1. The TN groups had a higher percentage of
current smokers (P < 0.001), while the mean age, sex distri-
bution were similar (both P > 0.05).
The genotype distribution of 5-HTTLPR between TN
patients controls are presented in Table 2. The 5-HTTLPR
genotype frequencies in the control group were in Hardy–
Weinberg equilibrium (P = 0.486), although those of TN
group were different from those expected under Hardy–
Weinberg equilibrium (P = 0.005). The rs25531 poly-
moprhimic distributions in TN and control groups were
in Hardy–Weinberg equilibrium (both P > 0.05). TN
Patients had a higher prevalence of 5-HTTLPR short-short
genotype than controls (35.66% vs. 17.14%, P < 0.001).
For allele analyses, TN patients had higher 5-HTTLPR
short allele frequency than controls (55.94% vs. 40.18%,
P = 0.045). Multivariate regression analyses showed that
the short-short genotype carriers had a significantly higher
risk for TN development after adjustments with age, sex,
and smoke (adjusted OR = 3.219, P < 0.001). With longTable 3 The genotype distribution of 5-HTTLPR gene polymorp
Genotype TN with BNI grade (IV-V) TN with BNI
5-HTTLPR Long-long 40 24.54% 34
Long-short 75 46.01% 39
Short-short 48 29.45% 8
Long 155 47.55% 107
short 171 52.45% 55
rs25531 AA 35 21.47% 17
AG 96 58.90% 41
GG 32 19.63% 23
A 166 50.92% 75
G 160 49.08% 87allele as reference, the OR for 5-HTTLPR short allele car-
riers was 1.891 (P = 0.045). However, the polymorphism at
rs25531 was not significant different between the TN
patients and controls (both P > 0.05, Table 2).
Before starting treatment, the TN patients were then
divided into two groups according to the pain severity:
those with severer pain severity (BMI grade: IV-V) and
those with less pain (BMI grade: I-III). TN Patients with
higher BNI scores had a higher prevalence of 5-HTTLPR
short-short genotype and short allele than those with lower
BNI scores (31% vs.15%, P < 0.001, Table 3). Multivariate re-
gression analyses showed that the 5-HTTLPR short-short
genotype carriage had a dramatically increased higher
chance for higher BNI score after adjustments with age,
sex and smoking status (adjusted OR = 5.1, P < 0.001).
With long allele as reference, the short allele carriage
represents significant higher risk for severer pain in TN
patients (adjusted OR = 2.146, P = 0.034). In contrast, the
polymorphism at rs25531 did not correlate to the BNI
score in this study (both P > 0.05, Table 3).
All patients were administrated carbamazepine treat-
ment and the pain severity was evaluated 6 months later.
A total of 17 patients discontinued the therapy due to
the side effect of carbamazepine and another 10 patientshism between TN patients stratified by the pain severity
grade scores (I-III) Adjusted OR 95% CI Adjusted P
41.98% 1.000
48.15% 1.635 0.898 2.975 0.107
9.88% 5.100 2.122 12.260 0.000
66.05% 1.000
33.95% 2.146 1.451 3.174 0.034
20.99% 1.000
50.62% 1.137 0.573 2.256 0.713
28.40% 0.676 0.307 1.488 0.329
46.30% 1.000
53.70% 0.831 0.570 1.212 0.336
Table 4 Summary of dose of carbamazepine and therapy






400 mg/day 34 55 0.620
800 mg/day 33 71
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total of 217 patients were evaluated at the end of 6 month,
of which 141 patients were assigned to improvement group
while the 76 were assigned to non-improvement group
based on their BNI scores. The doses of carbamazepine are
shown in Table 4. There was no significant dose differences
were noted. The genotypes of 5-HTTLPR and rs25531 gene
polymorphism are shown in Table 5. TN patients without
improvement tent to have significantly higher percentage of
short-short genotype and short allele frequencies compare
to those with improvement. Multivariate regression analyses
revealed that the short-short genotype and short allele are
associated with higher risk for treatment failure (adjusted
OR= 2.993, P = 0.009 and adjusted OR= 1.672, P = 0.011).
In contrast, the rs25531 polymorphism did not affect the
treatment response to carbamazepine in this study.
Discussion and conclusions
To the best of our knowledge, this is the first study re-
ported a close association between the 5-HTTLPR gene
polymorphism and the susceptibility to TN. In addition,
we found that the 5-HTTLPR gene polymorphism is re-
lated to the pain severity and the treatment response to
carbamazepine monotherapy in Chinese patients.Table 5 The genotype distribution of 5-HTTLPR and rs25531
treatment response
Genotype Treatment without improvement Treatme
5-HTTLPR Long-long 15 19.74% 46
Long-short 39 51.32% 72
Short-short 22 28.95% 23
Long 69 45.39% 164
short 83 54.61% 118
rs25531 AA 13 17.11% 31
AG 45 59.21% 76
GG 18 23.68% 34
A 71 46.71% 138
G 81 53.29% 144The association between 5-HT and pain disorder has
been reported. Increased 5-HT levels are noted in human
masseter muscle associated with pain and allodynia [12]
and following temporomandibular joint movement-evoked
pain [22]. Injection of exogenous 5-HT evokes hyperalgesia
in both humans, which is attenuated by local adminis-
tration of 5HT receptor antagonists [11,12,23]. Thus, the
modulation of 5-HT level may be a therapy target for pain
disorders. 5-HTT is one key regulator of 5-HT by removing
5-HT released into the synaptic cleft, thereby terminating
serotonergic neurotransmission [14,24].
5-HTT protein is encoded by the SLC6A4 gene whose
transcriptional activity is regulated by a number of varia-
tions [14]. The 5-HTTLPR polymorphism has been well
characterized to affect 5-HTT expression: The S and L
alleles in the 5-HTTLPR result in lower and higher
levels of 5-HTT expression, respectively [25]. The S/S
carriers exhibit lower expression of 5-HTT coupled with
reduced reuptake of 5-HT from the synapse, leading to
stronger psycho-pathological reactions to stressful expe-
riences compared to those with the L/L or L/S allele
[26]. The short (14-repeat) allele of 5-HTTLPR was shown
to have lower transcriptional activity leading to lower
neuronal serotonin reuptake [27]. Previous studies have
adequately documented the positive correlation between
the S/S genetic phenotype and anxiety-related personality
and susceptibility to mood disorders [28,29]. A recent study
suggests a significant association between the 5-HTTLPR
gene polymorphism and the new onset of depression
after PM implantation, especially in women or those
who were smokers [30].
Previous study showed an close association between
the polymorphism of 5-HTTLPR gene and migraine with
aura in children [31]. 5-HTT has important effects on ther-
mal pain perception in preclinical studies [32]. Additionally,
5-HTTLPR polymorphisms have been associated with dif-
ferences in thermal pain perception [33,34]. The short allele
of 5-HTTLPR is associated with emotional modulation ofgene polymorphism between TN patients stratified by
nt with improvement Adjusted OR 95% CI Adjusted P
32.62% 1.000
51.06% 1.661 0.824 3.349 0.154
16.31% 2.933 1.285 6.696 0.009
58.16% 1.000
41.84% 1.672 1.124 2.488 0.011
21.99% 1.000
53.90% 1.412 0.670 2.975 0.363
24.11% 1.262 0.532 2.994 0.597
48.94% 1.000
51.06% 1.093 0.737 1.623 0.851
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[18], however, another study argues that no relationship
between the polymorphism of 5-HTTLPR and pain percep-
tion in fibromyalgia patients and healthy controls [35]. The
discrepancy suggests the effect of 5-HTTLPR gene poly-
morphism might be condition specific. In this study, we
found that the gene polymorphism of 5-HTTLPR is closely
related to the risk for TN. The short-short genotype had
higher chance to develop TN in our studied cohort.
A previous clinical study tested the effect of escitalo-
pram in Denmark patients with peripheral neuropathic
pain. There was no significant association between pain
relief and the 5-HTTLPR polymorphism, however, the
researchers observed a weak tendency that more re-
sponders carry the short-short genotype and more
non-responders carry the long-long genotype [36]. In
contrast to this study, we found in this study that the short-
short genotype of 5-HTTLPR was more related to the treat-
ment failure to carbamazepine monotherapy. It should be
noticed that in that Demark study, only 48 patients were
enrolled. The sample size in our study is much larger, with
244 TN patients. The ethnic difference may also need to be
taken in account for this discrepancy.
Previous studies provided evidence that the genetic
polymorphism of several metabolic enzymes (e.g., several
isoenzymes of CYP450) and drug transporters (MDR1)
are associated with the therapeutically response to an-
algesics in pain condition [37,38]. The evaluation of
the gene polymorphism of these genes could give more
information about the carbamazepine metabolic profile of
each patient and, consequently, the therapeutic efficacy.
However, we did not evaluate the association of 5-HTTLPR
polymorphism with carbamazepine response stratified by
genetic metabolic profiles to estimate the real weight of
5-HTTLPR polymorphism in carbamazepine efficacy.
This is a major limitation of this study.
The other limitations of this study should also be ad-
dressed. Several limitations should be addressed in this
study. Firstly, this is a singe center study with a relatively
small size of patient sample. Thus the enrollment bias
may occur. Secondly, this study did not go deep to explore
the molecular mechanism under which the 5-HTTLPR
genotype influences the TN risk and treatment response.
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